Outcome of patients with de novo versus nevus-associated melanoma - 13/12/14
Abstract |
Background |
Prior reports indicate a wide range of melanomas in histopathologic contiguity with a nevus, and an associated nevus has unclear prognostic implications in melanoma.
Objective |
We sought to investigate the relationship among nevus-associated melanomas, sentinel lymph node status, and overall survival.
Methods |
We conducted a retrospective analysis of 850 patients with cutaneous melanoma and sentinel lymph node removed at Massachusetts General Hospital from 1998 through 2008 and meta-analysis of the literature.
Results |
Nevus-associated melanomas represented 28% (235/850) of cases and were significantly correlated with younger age (P = .03), truncal site (P = .0005), superficial spreading type (P < .0001), and absent ulceration (P = .005). There was no association with sentinel lymph node status (P = .94) and no survival difference between nevus-associated versus de novo melanoma (P = .41). Meta-analysis of over 4000 cases revealed a similar percentage of associated nevi (32%).
Limitations |
This was a retrospective study.
Conclusions |
Approximately 30% of melanomas are associated with a nevus. The presence of a nevus associated with a melanoma has no prognostic implication in sentinel lymph node status or overall survival.
Le texte complet de cet article est disponible en PDF.Key words : dysplastic nevus, melanoma, nevus, overall survival, precursor, sentinel lymph node biopsy
Plan
Dr Lobo is now affiliated with the Department of Dermatology, University of Sao Paulo, Brazil. |
|
Funding sources: None. |
|
Disclosure: Dr Sober is an investigator with MELA and a consultant for World Care. Drs Lin, Luo, Lobo, Tanabe, Cosimi, Tsao, and Duncan, and Ms Muzikansky have no conflicts of interest to declare. |
Vol 72 - N° 1
P. 54-58 - janvier 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?